Alto Neuroscience Inc (ANRO)

$12.11 +0.76 (6.70%)
Market Cap 384.49M
Revenue (ttm) 0.00
Net Income (ttm) -61.43M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.16
Volume 436,949
Avg Vol 1,960,164
Day's Range N/A - N/A
Shares Out 27.08M
Stochastic %K 26%
Beta 2.90
Analysts Strong Sell
Price Target $18.71

Company Profile

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinical trial to treat patients with major depressive disorder (MDD); ALTO-101, a novel small molecule ph...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 200 0412
Address:
650 Castro Street, Suite 450, Mountain View, United States
MOOSEN
MOOSEN Nov. 14 at 4:35 PM
$ANRO SCALPAH.
0 · Reply
MOOSEN
MOOSEN Nov. 14 at 4:07 PM
$ANRO BOTTOM FEEDING IS WHERE IT’S AT.
0 · Reply
MOOSEN
MOOSEN Nov. 14 at 3:27 PM
$ANRO CHUGACHUGA.
0 · Reply
MOOSEN
MOOSEN Nov. 14 at 12:13 AM
$ANRO LITTLE GUY.
0 · Reply
MOOSEN
MOOSEN Nov. 13 at 9:07 PM
$ANRO $SLS CONSIDERING THE FORMER DOWN HERE. EYES.
0 · Reply
Ccperk
Ccperk Nov. 13 at 4:14 PM
$ANRO huge double top is forming. This may be one for the record books…we will see in the coming days.
0 · Reply
JarvisFlow
JarvisFlow Nov. 13 at 12:35 PM
Baird has updated their rating for Alto Neuroscience ( $ANRO ) to Outperform with a price target of 22.
0 · Reply
BeardyMcBeard
BeardyMcBeard Nov. 13 at 6:25 AM
$ANRO
0 · Reply
JarvisFlow
JarvisFlow Nov. 12 at 7:38 PM
Jefferies updates rating for Alto Neuroscience ( $ANRO ) to Buy, target set at 15 → 25.
0 · Reply
MOOSEN
MOOSEN Nov. 12 at 7:07 PM
$SLS MOVING REMAINING $ANRO OVER.
0 · Reply
Latest News on ANRO
Alto Neuroscience Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Nov 12, 2025, 7:57 AM EST - 2 days ago

Alto Neuroscience Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Alto Neuroscience to Participate in Upcoming Investor Conferences

Oct 28, 2025, 7:34 AM EDT - 17 days ago

Alto Neuroscience to Participate in Upcoming Investor Conferences

Alto Neuroscience Announces $50 Million Private Placement Financing

Oct 20, 2025, 7:03 AM EDT - 25 days ago

Alto Neuroscience Announces $50 Million Private Placement Financing

Alto Neuroscience Announces Plans to Accelerate Development of ALTO-207 in Treatment Resistant Depression Following Successful Outcome from Recent FDA Meeting

Oct 20, 2025, 7:01 AM EDT - 25 days ago

Alto Neuroscience Announces Plans to Accelerate Development of ALTO-207 in Treatment Resistant Depression Following Successful Outcome from Recent FDA Meeting

Johnson Fistel, PLLP Investigates Claims on Behalf of Alto Neuroscience, Inc. Long-Term Shareholders

Oct 8, 2025, 9:56 AM EDT - 5 weeks ago

Johnson Fistel, PLLP Investigates Claims on Behalf of Alto Neuroscience, Inc. Long-Term Shareholders

Johnson Fistel, PLLP Investigates Claims on Behalf of Alto Neuroscience, Inc. Long-Term Shareholders

Oct 3, 2025, 10:51 AM EDT - 6 weeks ago

Johnson Fistel, PLLP Investigates Claims on Behalf of Alto Neuroscience, Inc. Long-Term Shareholders

Alto Neuroscience Receives FDA Fast Track Designation for ALTO-101 for the Treatment of Cognitive Impairment Associated with Schizophrenia

Oct 3, 2025, 7:34 AM EDT - 6 weeks ago

Alto Neuroscience Receives FDA Fast Track Designation for ALTO-101 for the Treatment of Cognitive Impairment Associated with Schizophrenia

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Alto Neuroscience

Sep 13, 2025, 11:50 AM EDT - 2 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Alto Neuroscience

Alto Neuroscience Announces Robust Replication of EEG Biomarker to Objectively Identify Patients with Cognitive Impairment in Schizophrenia

Sep 9, 2025, 7:09 AM EDT - 2 months ago

Alto Neuroscience Announces Robust Replication of EEG Biomarker to Objectively Identify Patients with Cognitive Impairment in Schizophrenia

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Alto Neuroscience

Aug 28, 2025, 5:40 PM EDT - 2 months ago

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Alto Neuroscience

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Alto Neuroscience

Aug 22, 2025, 10:15 AM EDT - 3 months ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Alto Neuroscience

Lawsuit DEADLINE: Investors who purchased over $100,000 worth of shares of Alto Neuroscience, Inc. (NYSE: ANRO) between Feb. and Oct. 2024 should contact the Shareholders Foundation

Aug 18, 2025, 9:45 AM EDT - 3 months ago

Lawsuit DEADLINE: Investors who purchased over $100,000 worth of shares of Alto Neuroscience, Inc. (NYSE: ANRO) between Feb. and Oct. 2024 should contact the Shareholders Foundation

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of September 19, 2025 in Alto Neuroscience, Inc. Lawsuit - ANRO

Aug 18, 2025, 8:45 AM EDT - 3 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of September 19, 2025 in Alto Neuroscience, Inc. Lawsuit - ANRO

Alto Neuroscience Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Aug 13, 2025, 4:10 PM EDT - 3 months ago

Alto Neuroscience Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Alto Neuroscience Appoints Biotech Industry Veteran, Raymond Sanchez, M.D., to Its Board of Directors

Aug 13, 2025, 8:03 AM EDT - 3 months ago

Alto Neuroscience Appoints Biotech Industry Veteran, Raymond Sanchez, M.D., to Its Board of Directors

Alto Neuroscience, Inc. Investigated for Breaches of Fiduciary Duty - Contact the DJS Law Group to Discuss Your Rights – ANRO

Aug 4, 2025, 2:46 PM EDT - 3 months ago

Alto Neuroscience, Inc. Investigated for Breaches of Fiduciary Duty - Contact the DJS Law Group to Discuss Your Rights – ANRO

ALTO NEUROSCIENCE, INC. (NYSE: ANRO) INVESTOR ALERT Investors With Large Losses in Alto Neuroscience, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights

Jul 22, 2025, 6:25 PM EDT - 4 months ago

ALTO NEUROSCIENCE, INC. (NYSE: ANRO) INVESTOR ALERT Investors With Large Losses in Alto Neuroscience, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights

Alto Neuroscience Highlights Peer-Reviewed Publication of PAX-D Study in The Lancet Psychiatry Demonstrating Robust Clinical Effects of Pramipexole for Patients with Treatment-Resistant Depression

Jun 30, 2025, 8:03 AM EDT - 4 months ago

Alto Neuroscience Highlights Peer-Reviewed Publication of PAX-D Study in The Lancet Psychiatry Demonstrating Robust Clinical Effects of Pramipexole for Patients with Treatment-Resistant Depression

Alto Neuroscience Identifies Biomarker and Reports Positive Pharmacodynamic Results from Exploratory Phase 2 Proof-of-Concept Trial of ALTO-203

Jun 26, 2025, 7:33 AM EDT - 5 months ago

Alto Neuroscience Identifies Biomarker and Reports Positive Pharmacodynamic Results from Exploratory Phase 2 Proof-of-Concept Trial of ALTO-203

Alto Neuroscience Announces Acquisition of Novel Dopamine Agonist Combination Product Candidate, Adding Late-Stage Readout in Treatment Resistant Depression Within Current Cash Runway

Jun 3, 2025, 6:03 AM EDT - 5 months ago

Alto Neuroscience Announces Acquisition of Novel Dopamine Agonist Combination Product Candidate, Adding Late-Stage Readout in Treatment Resistant Depression Within Current Cash Runway

Alto Neuroscience Presents Data at the 2025 American Society of Clinical Psychopharmacology Annual Meeting Reinforcing Safety and Tolerability Profile for ALTO-300 in Major Depressive Disorder

May 29, 2025, 8:03 AM EDT - 6 months ago

Alto Neuroscience Presents Data at the 2025 American Society of Clinical Psychopharmacology Annual Meeting Reinforcing Safety and Tolerability Profile for ALTO-300 in Major Depressive Disorder

Alto Neuroscience Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 14, 2025, 4:10 PM EDT - 6 months ago

Alto Neuroscience Reports First Quarter 2025 Financial Results and Recent Business Highlights

Alto Neuroscience Presents New Data at the Society of Biological Psychiatry Annual Meeting Underscoring Precision Psychiatry Approach

Apr 28, 2025, 8:03 AM EDT - 7 months ago

Alto Neuroscience Presents New Data at the Society of Biological Psychiatry Annual Meeting Underscoring Precision Psychiatry Approach

Alto Neuroscience to Participate in the JonesResearch Virtual CNS Day

Apr 22, 2025, 8:03 AM EDT - 7 months ago

Alto Neuroscience to Participate in the JonesResearch Virtual CNS Day

Alto Neuroscience Reports Full-Year 2024 Financial Results and Recent Business Highlights

Mar 20, 2025, 4:10 PM EDT - 8 months ago

Alto Neuroscience Reports Full-Year 2024 Financial Results and Recent Business Highlights

The Schall Law Firm Invites Investors With Losses In Alto Neuroscience, Inc. To Join A Securities Fraud Investigation

Mar 1, 2025, 11:00 AM EST - 9 months ago

The Schall Law Firm Invites Investors With Losses In Alto Neuroscience, Inc. To Join A Securities Fraud Investigation

Alto Neuroscience Announces U.S. Patent Granted Covering ALTO-300 as a Treatment for Patients with Major Depressive Disorder Characterized by an Electroencephalogram Biomarker

Feb 19, 2025, 8:03 AM EST - 9 months ago

Alto Neuroscience Announces U.S. Patent Granted Covering ALTO-300 as a Treatment for Patients with Major Depressive Disorder Characterized by an Electroencephalogram Biomarker

Alto Neuroscience Announces Favorable Outcome from Interim Analysis of ALTO-300 Phase 2b Major Depressive Disorder Trial

Feb 12, 2025, 8:03 AM EST - 9 months ago

Alto Neuroscience Announces Favorable Outcome from Interim Analysis of ALTO-300 Phase 2b Major Depressive Disorder Trial

The Schall Law Firm Invites Investors With Losses To Join An Investigation Into Alto Neuroscience, Inc. For Securities Fraud

Feb 2, 2025, 11:00 AM EST - 10 months ago

The Schall Law Firm Invites Investors With Losses To Join An Investigation Into Alto Neuroscience, Inc. For Securities Fraud

MOOSEN
MOOSEN Nov. 14 at 4:35 PM
$ANRO SCALPAH.
0 · Reply
MOOSEN
MOOSEN Nov. 14 at 4:07 PM
$ANRO BOTTOM FEEDING IS WHERE IT’S AT.
0 · Reply
MOOSEN
MOOSEN Nov. 14 at 3:27 PM
$ANRO CHUGACHUGA.
0 · Reply
MOOSEN
MOOSEN Nov. 14 at 12:13 AM
$ANRO LITTLE GUY.
0 · Reply
MOOSEN
MOOSEN Nov. 13 at 9:07 PM
$ANRO $SLS CONSIDERING THE FORMER DOWN HERE. EYES.
0 · Reply
Ccperk
Ccperk Nov. 13 at 4:14 PM
$ANRO huge double top is forming. This may be one for the record books…we will see in the coming days.
0 · Reply
JarvisFlow
JarvisFlow Nov. 13 at 12:35 PM
Baird has updated their rating for Alto Neuroscience ( $ANRO ) to Outperform with a price target of 22.
0 · Reply
BeardyMcBeard
BeardyMcBeard Nov. 13 at 6:25 AM
$ANRO
0 · Reply
JarvisFlow
JarvisFlow Nov. 12 at 7:38 PM
Jefferies updates rating for Alto Neuroscience ( $ANRO ) to Buy, target set at 15 → 25.
0 · Reply
MOOSEN
MOOSEN Nov. 12 at 7:07 PM
$SLS MOVING REMAINING $ANRO OVER.
0 · Reply
Swing_Tradr
Swing_Tradr Nov. 12 at 4:39 PM
$ANRO TradrSense Pro found this play on 11/7/2025 and is setup for a nice profit. Here's what TradrSense Pro had to say: "The trade plan is designed to capitalize on this setup. The entry price of $11.13 is strategically chosen because the price is already showing strength above the 20-day SMA, confirming the momentum and making it a solid entry point. The stop-loss at $6.72 is set at the 14-day low, which is a clear support level that helps define the risk, ensuring that downside exposure is minimized."
1 · Reply
MOOSEN
MOOSEN Nov. 12 at 4:25 PM
$ANRO THIS THANG HAS NO MF CHILL.
0 · Reply
d_risk
d_risk Nov. 12 at 4:22 PM
$ANRO - Alto Neuroscience Inc. Common Stock - 10Q - Updated Risk Factors ANRO flags new legal risks from recent securities class action and derivative lawsuits related to its IPO and disclosures, warning of possible financial and management impacts. #Biotechnology #FinancialImpact #IPODisclosure #SecuritiesLitigation #LegalRisks 🟢 Added 🟠 Removed https://d-risk.ai/ANRO/10-Q/2025-11-12
1 · Reply
notreload_ai
notreload_ai Nov. 12 at 4:14 PM
Jefferies boosts $ANRO price target to $25, citing upcoming Phase II data and investor interest in its precision psychiatry treatments. https://notreload.xyz/jefferies-raises-price-target-for-alto-neuroscience/
0 · Reply
QHH
QHH Nov. 12 at 12:27 PM
$ANRO "There're 7 recent analysts, rating it as "Strong Buy", with a target price of ~24.00$".
0 · Reply
MOOSEN
MOOSEN Nov. 11 at 6:33 PM
$SLS $ANRO SCALPS ROLLING IN DOWN HERE.
0 · Reply
Ccperk
Ccperk Nov. 11 at 5:57 PM
$ANRO rung the opening bell this morning so I searched why would a non-IPO company ring the bell? Put it this way, all the reasons are good. Not financial advice GL 👍
0 · Reply
drtowns
drtowns Nov. 11 at 5:16 PM
$ANRO
0 · Reply
MOOSEN
MOOSEN Nov. 10 at 8:47 PM
$ANRO OOO BOY.
0 · Reply
Dirk1969
Dirk1969 Nov. 10 at 6:58 PM
$ANRO next $KYTX ✅📈
1 · Reply
MOOSEN
MOOSEN Nov. 10 at 6:53 PM
$ANRO PUSHA.
0 · Reply
ZacksResearch
ZacksResearch Nov. 10 at 5:04 PM
Biotech earnings breakout ahead? 🧬 $ANRO, $AUTL, $ASND, and $IMRX are all gearing up to report Q3 numbers that could beat Street estimates — a setup that could spark serious upside moves if results deliver. Full biotech earnings preview here 👉 https://www.zacks.com/stock/news/2788687/are-these-4-biotech-stocks-set-to-beat-q3-earnings-estimates?cid=sm-stocktwits-2-2788687-teaser-20298&ADID=SYND_STOCKTWITS_TWEET_2_2788687_TEASER_20298
0 · Reply